This site is intended for health professionals only

Published on 23 March 2010

Share this story:
Twitter
LinkedIn

Plavix trial results “positive”

teaser

The life expectancy of heart attack patients who have not had angioplasty treatment can be greatly improved with use of the drug Plavix, research has shown.

An 18-month study published in the Journal of the American College of Cardiology, the first to look at the treatment, found that 28.1% of a group treated with Plavix died compared to 32.2% of those who had not been given the drug.

The statistically significant difference could have “considerable clinical impact”, researchers said.

Heart failure is a disease in which the heart is unable to pump enough blood around the body. It can be alleviated by angioplasty, a non-surgical procedure that can help clear blocked arteries.

Plavix, known generically as clopidogrel, is made by Sanofi-Aventis and Bristol-Myers Squibb.

Copyright Press Association 2010

Journal of the American College of Cardiology



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn